| RT em cabeça e pescoço >45-75Gy(55 Kang S, Seo JW, Sa HS. Cancer-associated epiphora: a retrospective analysis of referrals to a tertiary oculoplastic practice. Br J Ophthalmol. 2017;101(11):1566-9.,77 Weber DC, Chan AW, Lessell S, McIntyre JF, Goldberg SI, Bussiere MR, et al. Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons. Radiother Oncol. 2006;81(3):243-9.) |
DNL |
Não |
Intubação antes RT |
DCR, C-DCR |
RIT >150 mCi(1414 Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab. 2002;87(12):5817-20.
15 Morgenstern KE, Vadysirisack DD, Zhang Z, Cahill KV, Foster JA, Burns JA, et al. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthalmic Plast Reconstr Surg. 2005;21(5):337-44.
16 Burns JA, Morgenstern KE, Cahill KV, Foster JA, Jhiang SM, Kloos RT. Nasolacrimal obstruction secondary to I(131) therapy. Ophthalmic Plast Reconstr Surg. 2004;20(2):126-9.
17 Fonseca FL, Lunardelli P, Matayoshi S. Obstrução de vias lacrimais associada ao tratamento radioiodoterápico de carcinoma de tireoide [Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma]. Arq Bras Oftalmol. 2012;75(2):97-100. Portuguese-1818 da Fonseca FL, Yamanaka PK, Kato JM, Matayoshi S. Lacrimal System Obstruction After Radioiodine Therapy in Differentiated Thyroid Carcinomas: A Prospective Comparative Study. Thyroid. 2016;26(12):1761-7.) |
DNL e SL (obstrução completa) |
Não |
- |
DCR |
| S-1(3535 Esmaeli B, Ahmadi MA, Rivera E, Valero V, Hutto T, Jackson DM, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol. 2002;120(9):1180-2.) |
DNL > ponto > canalículo |
Não |
Intubação |
DCR, C-DCR |
| 5-FU por tempo curto(1919 Hamersley J, Luce JK, Florentz TR, Burkholder MM, Pepper JJ. Excessive lacrimation from fluorouracil treatment. JAMA. 1973;225(7):747-8.,2020 Christophidis N, Vajda FJ, Lucas I, Louis WJ. Ocular side effects with 5-fluorouracil. Aust N Z J Med. 1979;9(2):143-4.) |
Ponto, canalículo (sem fibrose) |
Sim |
Sondagem, irrigação e esteroide tópico |
- |
5-FU por tempo prolongado(2424 Prasad S, Kamath GG, Phillips RP. Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy. Acta Ophthalmol Scand. 2000;78(1):110-3.
25 Eiseman AS, Flanagan JC, Brooks AB, Mitchell EP, Pemberton CH. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthalmic Plast Reconstr Surg. 2003;19(3):216-24.
26 Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs. 1998;9(9):817-23.
27 Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005;140(2):325-7.-2828 Kim N, Park C, Park DJ, Kim HH, Kim S, Kim YJ, et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012;23(8):2065-71.) |
Ponto, canalículo (sem fibrose) |
Sim |
Intubação |
- |
| Ponto, canalículo (com fibrose) |
Não |
- |
C-DCR |
| Docetaxel a cada 3 semanas ou por tempo curto (neoadjuvante)(3838 Leyssens B, Wildiers H, Lobelle JP, Gillis A, Paridaens R, Mombaerts I. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Ann Oncol. 2010;21(2):419-43.,4040 Juniat VAR, Rajak S. The use of prophylactic Nunchaku stents to reduce the risk of nasolacrimal duct obstruction in patients with midfacial tumours undergoing radiotherapy. Orbit. 2017;36(5):298-300.) |
Canalículo e DNL |
Sim |
Sondagem, irrigação e esteroide tópico |
- |
| Docetaxel semanal ou por tempo prolongado (paliativo)(3838 Leyssens B, Wildiers H, Lobelle JP, Gillis A, Paridaens R, Mombaerts I. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Ann Oncol. 2010;21(2):419-43.,4040 Juniat VAR, Rajak S. The use of prophylactic Nunchaku stents to reduce the risk of nasolacrimal duct obstruction in patients with midfacial tumours undergoing radiotherapy. Orbit. 2017;36(5):298-300.) |
Canalículo e DNL (sem fibrose) |
Sim |
Intubação ao sinal de estenose |
- |
| Canalículo e DNL (com fibrose) |
Não |
- |
DCR, C-DCR |
Thumbnail
Fonte: Autoria própria (Juliana Mika Kato).